首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

2160704

疼痛管理和神經調控設備市場預測至2034年：按設備類型、應用、最終用戶和地區分類的全球分析

Pain Management & Neuromodulation Devices Market Forecasts to 2034 - Global Analysis By Device Type, Application, End User and By Geography

出版日期: 2026年10月22日 | 出版商:

Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

根據 Stratistics MRC 的數據，預計到 2026 年，全球疼痛管理和神經調節設備市場規模將達到 77 億美元，並在預測期內以 11.8% 的複合年成長率成長，到 2034 年將達到 189 億美元。

疼痛管理和神經調控設備是指用於透過標靶治療方法來管理和緩解急性或持續性疼痛的專用醫療技術。此類別包括脊髓刺激系統、周邊神經刺激設備、經皮電神經刺激（TENS）設備、植入式輸液幫浦和射頻消融術技術。這些解決方案透過改變神經活動、阻斷疼痛訊號或治療受影響部位附近的區域來發揮作用。它們廣泛用於治療神經病變疼痛、神經性疼痛、肌肉骨骼疾病、術後不適以及其他傳統疼痛管理方法無法充分緩解的疾病。

根據美國疾病管制與預防中心 (CDC) 的數據，2023 年，美國有 24.3% 的成年人患有慢性疼痛，其中 8.5% 的人患有嚴重的慢性疼痛，經常限制他們的日常活動或工作活動。

慢性疼痛盛行率上升

慢性疼痛盛行率的不斷上升正顯著推動「疼痛管理和神經調控設備市場」的成長。與老齡化相關的疾病、肌肉骨骼問題、糖尿病神經病變、癌症以及長期術後不適等，都持續催生了對專業疼痛治療的需求。神經調控設備能夠精準地調節異常神經活動，同時改善患者的功能。隨著醫生和醫療保健專業人員越來越重視針對慢性疼痛的個人化、微創治療方法，醫療機構對先進疼痛管理和神經調控技術的應用預計將持續成長。

先進神經控制裝置高成本

先進神經調控技術的高成本可能會阻礙疼痛管理和神經調控設備市場的發展。植入式刺激系統、注射設備、植入手術以及相關的臨床服務都會對患者和醫療機構造成沉重的經濟負擔。此外，程式設計、監測、後續護理、維護以及最終的設備更換等都會進一步增加成本。這些經濟障礙可能導致患者推遲接受先進的疼痛治療，從而限制其普及，尤其是在醫療體系和市場發展中，確保治療費用可負擔性仍然是一個重要問題。

數位技術與遠端監控的融合

數位技術和遠端監測的普及應用為疼痛管理和神經調控設備市場創造了巨大的成長機會。互聯的神經調控系統、智慧型手機應用程式、雲端平台和遠端調節功能，能夠幫助醫療專業人員追蹤患者病情並最佳化治療方案。人工智慧 (AI) 和先進的分析技術，透過評估患者反應並輔助設定最佳刺激參數，可以進一步促進個人化治療。隨著互聯醫療的擴展，這些功能將加速神經調控技術的應用，從而實現更靈活、個人化和高效的疼痛管理。

嚴格的監管要求和核准挑戰

複雜的法律規範和冗長的產品核可流程可能會阻礙疼痛管理和神經調控設備市場的成長。企業在產品上市前必須提供大量關於安全性、臨床療效、可靠性和耐用性的證據。各國監理體系的差異會增加合規要求和研發成本。此外，商業化後的持續監測和報告也會增加營運負擔。核准延遲可能會推遲創新產品的上市，而中小製造商可能難以獲得必要的資源和成本來滿足監管合規要求。

新型冠狀病毒（COVID-19）的影響：

新冠肺炎疫情對疼痛管理和神經調控設備市場造成了負面影響，原因包括擇期手術延遲、就診量減少以及醫療資源轉移至對抗疫情。旅行限制和疼痛診所的暫時關閉擾亂了植入手術和患者監測。全球供應鏈的中斷也為醫療設備和關鍵零件的採購帶來了挑戰。然而，遠端醫療服務和遠距監測技術使得部分患者的治療得以繼續進行。疫情過後，醫療機構的重新開放、手術延誤的緩解以及對慢性疼痛治療的持續需求，共同推動了市場需求的復甦。

在預測期內，脊髓刺激（SCS）領域預計將佔據最大的市場佔有率。

預計在預測期內，脊髓刺激（SCS）療法將佔據最大的市場佔有率，這主要得益於其在慢性疼痛和神經病變疼痛治療領域的廣泛應用。此療法利用電刺激作用於神經通路，抑制疼痛訊號向大腦的傳遞。它常用於治療術後腰痛、複雜性局部疼痛症候群和難治性神經病變疼痛等持續性疾病。包括可充電設備、先進的程式功能和改進的電極設計在內的技術進步，提高了治療能力和臨床療效，從而提高了患者和醫療專業人員的接受度。

在預測期內，偏頭痛和叢集性頭痛細分市場預計將呈現最高的複合年成長率。

在預測期內，偏頭痛和叢集性頭痛細分市場預計將呈現最高的成長率，這主要得益於神經調控療法在治療難治性頭痛症狀方面的接受度不斷提高。反覆發作的嚴重頭痛會嚴重影響日常生活，降低生活品質。神經調控技術能夠對與頭痛發作相關的神經路徑進行標靶刺激。臨床應用的不斷拓展、醫療設備的持續創新以及人們對傳統藥物療法以外的替代療法的日益關注，都促使越來越多的患者開始接受這些技術，用於治療持續性偏頭痛和叢集性頭痛症狀。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其先進的醫療保健體系、專業的治療設施以及對先進醫療技術的高度接受度。該地區擁有廣泛的醫院、疼痛管理中心、神經科設施和復健機構網路，為神經調控療法的推廣應用提供了有力支持。人們對慢性疼痛管理的日益重視、專業專家的普及以及設備技術的不斷進步，都進一步推動了神經調控療法的普及。此外，北美成熟的行業參與者和豐富的臨床經驗也進一步鞏固了其在全球疼痛管理和神經調控領域的領先地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於人們對先進治療方案的認知不斷提高以及醫療基礎設施的改善。醫療支出的成長、專科醫生能力的提升以及創新醫療設備取得管道的改善，正在推動全部區域神經調控技術的普及應用。慢性疼痛盛行率的上升和人口老化進一步加劇了對有效疼痛管理方案的需求。此外，技術的持續進步、醫療設施的擴建以及訓練有素的專業人員的儲備，也為亞太地區新興市場和成熟市場的神經調控技術發展創造了機會。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

企業概況
- 對其他市場參與者（最多 3 家公司）進行全面分析
- 對主要公司進行SWOT分析（最多3家公司）
區域細分
- 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性評估）。
競爭性標竿分析
- 根據產品系列、企業發展和策略聯盟對重點公司進行基準分析。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 比利時
- 瑞典
- 瑞士
- 波蘭
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 韓國
- 澳洲
- 印尼
- 泰國
- 馬來西亞
- 新加坡
- 越南
- 其他亞太國家
南美洲
- 巴西
- 阿根廷
- 哥倫比亞
- 智利
- 秘魯
- 其他南美國家
世界其他地區（RoW）
- 中東
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 卡達
  - 以色列
  - 其他中東國家
- 非洲
  - 南非
  - 埃及
  - 摩洛哥
  - 其他非洲國家

第9章戰略市場資訊

工業價值網路和供應鏈評估
空白區域和機會地圖
產品演進與市場生命週期分析
通路、經銷商和打入市場策略的評估

第10章：產業趨勢與策略舉措

併購
夥伴關係、聯盟和合資企業
新產品發布和認證
擴大生產能力和投資
其他策略舉措

第11章：公司簡介

Abbott
BIOTRONIK
Boston Scientific
CEFALY Technology
electroCore
LivaNova
Medtronic
NeuroPace
Nevro
Saluda Medical
Theranica
Stryker Corporation
Johnson & Johnson
B. Braun SE
Bioventus
Mainstay Medical
Curonix
Nervonik

簡介目錄圖表

Product Code: SMRC40190

According to Stratistics MRC, the Global Pain Management & Neuromodulation Devices Market is accounted for $7.7 billion in 2026 and is expected to reach $18.9 billion by 2034 growing at a CAGR of 11.8% during the forecast period. Pain Management & Neuromodulation Devices comprise specialized medical technologies used to manage and alleviate acute or persistent pain through targeted therapeutic approaches. The category covers spinal cord stimulation systems, peripheral nerve stimulation devices, transcutaneous electrical nerve stimulation equipment, implantable infusion pumps, and radiofrequency ablation technologies. These solutions work by altering nerve activity, interrupting pain signals, or providing treatment close to affected tissues. They are utilized across chronic and neuropathic pain, musculoskeletal disorders, postoperative discomfort, and other conditions where conventional pain-management approaches may provide insufficient relief.

According to the U.S. CDC, 24.3% of U.S. adults experienced chronic pain in 2023, while 8.5% experienced high-impact chronic pain that frequently limited life or work activities.

Market Dynamics:

Driver:

Rising prevalence of chronic pain conditions

Increasing rates of chronic pain are significantly supporting growth in the Pain Management & Neuromodulation Devices Market. Conditions associated with aging, musculoskeletal problems, diabetic neuropathy, cancer, and prolonged postsurgical discomfort create sustained demand for specialized pain therapies. Neuromodulation devices offer targeted methods for modifying abnormal neural activity while supporting improved patient functionality. As physicians and healthcare providers emphasize personalized, minimally invasive approaches for persistent pain, the adoption of sophisticated pain-management and neuromodulation technologies is expected to continue increasing across healthcare facilities.

Restraint:

High cost of advanced neuromodulation devices

High expenses associated with sophisticated neuromodulation technologies may hinder expansion of the Pain Management & Neuromodulation Devices Market. Implantable stimulation systems, infusion devices, implantation procedures, and related clinical services can create significant financial burdens for patients and healthcare providers. Costs may also increase through programming, monitoring, follow-up care, maintenance, and eventual device replacement. These economic barriers may cause patients to postpone advanced pain therapies and limit adoption, particularly within developing healthcare systems and markets where affordability remains a major concern.

Opportunity:

Integration of digital technologies and remote monitoring

The adoption of digital technologies and remote monitoring creates promising growth opportunities for the Pain Management & Neuromodulation Devices Market. Connected neuromodulation systems, smartphone applications, cloud-based platforms, and remote adjustment features can help healthcare professionals track patients and optimize therapies. Artificial intelligence and advanced analytics can further contribute to individualized therapy by evaluating patient responses and supporting optimized stimulation parameters. As connected healthcare expands, these capabilities can broaden neuromodulation adoption and enable more flexible, personalized, and efficient pain management.

Threat:

Stringent regulatory requirements and approval challenges

Complex regulatory frameworks and extended product approval timelines can challenge growth in the Pain Management & Neuromodulation Devices Market. Companies are required to provide extensive evidence regarding safety, clinical performance, reliability, and durability before commercialization. Differences between national regulatory systems can increase compliance requirements and development expenses. Ongoing monitoring and reporting after commercialization may create additional operational responsibilities. Approval delays can postpone innovative product launches, while smaller manufacturers may struggle with regulatory costs and resources.

Covid-19 Impact:

The COVID-19 pandemic adversely affected the Pain Management & Neuromodulation Devices Market through delayed elective procedures, fewer clinical consultations, and the redirection of medical resources toward COVID-19 care. Limited mobility and temporary pain-clinic closures interrupted implantation procedures and patient monitoring. Disruptions across global supply chains also created challenges in obtaining devices and essential components. Nevertheless, telehealth services and remote monitoring technologies helped maintain care for selected patients. Following the pandemic, reopening healthcare facilities, clearing procedure backlogs, and persistent chronic pain needs contributed to renewed demand and market recovery.

The spinal cord stimulation (SCS) segment is expected to be the largest during the forecast period

The spinal cord stimulation (SCS) segment is expected to account for the largest market share during the forecast period, supported by its widespread application in chronic and neuropathic pain management. The approach uses electrical stimulation to influence neural pathways and reduce the transmission of pain signals to the brain. It is commonly applied for persistent conditions including failed back surgery syndrome, complex regional pain syndrome, and difficult-to-treat neuropathic pain. Developments such as rechargeable devices, sophisticated programming options, and improved electrode designs have enhanced treatment capabilities, clinical effectiveness, and acceptance among patients and healthcare professionals.

The migraine & cluster headaches segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the migraine & cluster headaches segment is predicted to witness the highest growth rate, driven by greater acceptance of neuromodulation for challenging headache conditions. Recurrent and severe headaches can significantly disrupt normal activities and reduce quality of life. Neuromodulation technologies offer targeted stimulation that influences neural pathways associated with headache development. Increasing clinical utilization, ongoing device innovation, and rising interest in alternatives to conventional medication are contributing to greater adoption of these technologies for patients experiencing persistent migraine and cluster headache symptoms.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, benefiting from sophisticated healthcare systems, specialized treatment facilities, and high acceptance of advanced medical technologies. Its extensive network of hospitals, pain-management centers, neurological facilities, and rehabilitation providers supports the use of neuromodulation therapies. Increasing recognition of chronic pain management, access to skilled specialists and ongoing improvements in device technologies further encourage adoption. The presence of established industry participants and substantial clinical expertise additionally reinforces North America's strong position within the global pain-management and neuromodulation landscape.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, supported by greater awareness of advanced therapeutic options and improvements in healthcare infrastructure. Increasing healthcare spending, expanding specialist capabilities, and better access to innovative devices are encouraging adoption throughout the region. Growing chronic pain prevalence and demographic aging are further increasing the need for effective pain-management solutions. Moreover, continued technological progress, expanding healthcare facilities, and improved availability of trained specialists are establishing favorable opportunities for neuromodulation technologies across both developing and mature Asia Pacific healthcare markets.

Key players in the market

Some of the key players in Pain Management & Neuromodulation Devices Market include Abbott, BIOTRONIK, Boston Scientific, CEFALY Technology, electroCore, LivaNova, Medtronic, NeuroPace, Nevro, Saluda Medical, Theranica, Stryker Corporation, Johnson & Johnson, B. Braun SE, Bioventus, Mainstay Medical, Curonix and Nervonik.

Key Developments:

In January 2026, Boston Scientific Corporation and Penumbra, Inc. announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in cash and stock transaction that values Penumbra at $374 per share, reflecting an enterprise value of approximately $14.5 billion.

In November 2025, Abbott and Exact Sciences announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions more people. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per common share, representing a total equity value of approximately $21 billion.

Device Types Covered:

Spinal Cord Stimulation (SCS)
Deep Brain Stimulation (DBS)
Sacral Nerve Stimulation (SNS)
Vagus Nerve Stimulation (VNS)
Peripheral Nerve Stimulation (PNS)
Transcutaneous Electrical Nerve Stimulation (TENS)
Radiofrequency Ablation
Intrathecal Drug Delivery

Applications Covered:

Chronic Pain
Movement Disorders
Psychiatric Disorders
Epilepsy
Urinary & Fecal Incontinence
Migraine & Cluster Headaches

End Users Covered:

Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Home Care

Regions Covered:

North America
- United States
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
Rest of the World (RoW)
- Middle East
Saudi Arabia
United Arab Emirates
Qatar
Israel
Rest of Middle East
- Africa
South Africa
Egypt
Morocco
Rest of Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations

2 Research Framework

2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
- 2.4.1 Data Collection (Primary and Secondary)
- 2.4.2 Data Modeling and Estimation Techniques
- 2.4.3 Data Validation and Triangulation
- 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

4.1 Porter's Five Forces Analysis
- 4.1.1 Supplier Bargaining Power
- 4.1.2 Buyer Bargaining Power
- 4.1.3 Threat of Substitutes
- 4.1.4 Threat of New Entrants
- 4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison

5 Global Pain Management & Neuromodulation Devices Market, By Device Type

5.1 Spinal Cord Stimulation (SCS)
5.2 Deep Brain Stimulation (DBS)
5.3 Sacral Nerve Stimulation (SNS)
5.4 Vagus Nerve Stimulation (VNS)
5.5 Peripheral Nerve Stimulation (PNS)
5.6 Transcutaneous Electrical Nerve Stimulation (TENS)
5.7 Radiofrequency Ablation
5.8 Intrathecal Drug Delivery

6 Global Pain Management & Neuromodulation Devices Market, By Application

6.1 Chronic Pain
6.2 Movement Disorders
6.3 Psychiatric Disorders
6.4 Epilepsy
6.5 Urinary & Fecal Incontinence
6.6 Migraine & Cluster Headaches

7 Global Pain Management & Neuromodulation Devices Market, By End User

7.1 Hospitals
7.2 Ambulatory Surgical Centers
7.3 Specialty Clinics
7.4 Home Care

8 Global Pain Management & Neuromodulation Devices Market, By Geography

8.1 North America
- 8.1.1 United States
- 8.1.2 Canada
- 8.1.3 Mexico
8.2 Europe
- 8.2.1 United Kingdom
- 8.2.2 Germany
- 8.2.3 France
- 8.2.4 Italy
- 8.2.5 Spain
- 8.2.6 Netherlands
- 8.2.7 Belgium
- 8.2.8 Sweden
- 8.2.9 Switzerland
- 8.2.10 Poland
- 8.2.11 Rest of Europe
8.3 Asia Pacific
- 8.3.1 China
- 8.3.2 Japan
- 8.3.3 India
- 8.3.4 South Korea
- 8.3.5 Australia
- 8.3.6 Indonesia
- 8.3.7 Thailand
- 8.3.8 Malaysia
- 8.3.9 Singapore
- 8.3.10 Vietnam
- 8.3.11 Rest of Asia Pacific
8.4 South America
- 8.4.1 Brazil
- 8.4.2 Argentina
- 8.4.3 Colombia
- 8.4.4 Chile
- 8.4.5 Peru
- 8.4.6 Rest of South America
8.5 Rest of the World (RoW)
- 8.5.1 Middle East
  - 8.5.1.1 Saudi Arabia
  - 8.5.1.2 United Arab Emirates
  - 8.5.1.3 Qatar
  - 8.5.1.4 Israel
  - 8.5.1.5 Rest of Middle East
- 8.5.2 Africa
  - 8.5.2.1 South Africa
  - 8.5.2.2 Egypt
  - 8.5.2.3 Morocco
  - 8.5.2.4 Rest of Africa

9 Strategic Market Intelligence

9.1 Industry Value Network and Supply Chain Assessment
9.2 White-Space and Opportunity Mapping
9.3 Product Evolution and Market Life Cycle Analysis
9.4 Channel, Distributor, and Go-to-Market Assessment

10 Industry Developments and Strategic Initiatives

10.1 Mergers and Acquisitions
10.2 Partnerships, Alliances, and Joint Ventures
10.3 New Product Launches and Certifications
10.4 Capacity Expansion and Investments
10.5 Other Strategic Initiatives

11 Company Profiles

11.1 Abbott
11.2 BIOTRONIK
11.3 Boston Scientific
11.4 CEFALY Technology
11.5 electroCore
11.6 LivaNova
11.7 Medtronic
11.8 NeuroPace
11.9 Nevro
11.10 Saluda Medical
11.11 Theranica
11.12 Stryker Corporation
11.13 Johnson & Johnson
11.14 B. Braun SE
11.15 Bioventus
11.16 Mainstay Medical
11.17 Curonix
11.18 Nervonik

簡介目錄圖表

List of Tables

Table 1 Global Pain Management & Neuromodulation Devices Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Pain Management & Neuromodulation Devices Market Outlook, By Device Type (2023-2034) ($MN)
Table 3 Global Pain Management & Neuromodulation Devices Market Outlook, By Spinal Cord Stimulation (SCS) (2023-2034) ($MN)
Table 4 Global Pain Management & Neuromodulation Devices Market Outlook, By Deep Brain Stimulation (DBS) (2023-2034) ($MN)
Table 5 Global Pain Management & Neuromodulation Devices Market Outlook, By Sacral Nerve Stimulation (SNS) (2023-2034) ($MN)
Table 6 Global Pain Management & Neuromodulation Devices Market Outlook, By Vagus Nerve Stimulation (VNS) (2023-2034) ($MN)
Table 7 Global Pain Management & Neuromodulation Devices Market Outlook, By Peripheral Nerve Stimulation (PNS) (2023-2034) ($MN)
Table 8 Global Pain Management & Neuromodulation Devices Market Outlook, By Transcutaneous Electrical Nerve Stimulation (TENS) (2023-2034) ($MN)
Table 9 Global Pain Management & Neuromodulation Devices Market Outlook, By Radiofrequency Ablation (2023-2034) ($MN)
Table 10 Global Pain Management & Neuromodulation Devices Market Outlook, By Intrathecal Drug Delivery (2023-2034) ($MN)
Table 11 Global Pain Management & Neuromodulation Devices Market Outlook, By Application (2023-2034) ($MN)
Table 12 Global Pain Management & Neuromodulation Devices Market Outlook, By Chronic Pain (2023-2034) ($MN)
Table 13 Global Pain Management & Neuromodulation Devices Market Outlook, By Movement Disorders (2023-2034) ($MN)
Table 14 Global Pain Management & Neuromodulation Devices Market Outlook, By Psychiatric Disorders (2023-2034) ($MN)
Table 15 Global Pain Management & Neuromodulation Devices Market Outlook, By Epilepsy (2023-2034) ($MN)
Table 16 Global Pain Management & Neuromodulation Devices Market Outlook, By Urinary & Fecal Incontinence (2023-2034) ($MN)
Table 17 Global Pain Management & Neuromodulation Devices Market Outlook, By Migraine & Cluster Headaches (2023-2034) ($MN)
Table 18 Global Pain Management & Neuromodulation Devices Market Outlook, By End User (2023-2034) ($MN)
Table 19 Global Pain Management & Neuromodulation Devices Market Outlook, By Hospitals (2023-2034) ($MN)
Table 20 Global Pain Management & Neuromodulation Devices Market Outlook, By Ambulatory Surgical Centers (2023-2034) ($MN)
Table 21 Global Pain Management & Neuromodulation Devices Market Outlook, By Specialty Clinics (2023-2034) ($MN)
Table 22 Global Pain Management & Neuromodulation Devices Market Outlook, By Home Care (2023-2034) ($MN)